Primary outcomeb | | | | |
Polypharmacy versus Controls | 1.40 (0.88 to 2.23) | 0.16 | 1.05 (0.65 to 1.68) | 0.85 |
Hyperpolypharmacy versus Controls | 2.00 (1.26 to 3.16) | 0.003 | 1.29 (0.80 to 2.07) | 0.30 |
Super hyperpolypharmacy versus Controls | 2.65 (1.66 to 4.23) | <0.001 | 1.37 (0.83 to 2.25) | 0.22 |
|
Cardiovascular death | | | | |
Polypharmacy versus Controls | 0.90 (0.51 to 1.60) | 0.73 | 0.70 (0.39 to 1.25) | 0.23 |
Hyperpolypharmacy versus Controls | 0.94 (0.53 to 1.66) | 0.83 | 0.64 (0.35 to 1.18) | 0.15 |
Super hyperpolypharmacy versus Controls | 1.08 (0.60 to 1.96) | 0.80 | 0.66 (0.34 to 1.26) | 0.21 |
|
All-cause death | | | | |
Polypharmacy versus Controls | 0.84 (0.54 to 1.28) | 0.41 | 0.60 (0.39 to 0.94) | 0.025 |
Hyperpolypharmacy versus Controls | 1.00 (0.65 to 1.52) | 0.99 | 0.61 (0.39 to 0.96) | 0.031 |
Super hyperpolypharmacy versus Controls | 0.95 (0.61 to 1.49) | 0.83 | 0.51 (0.31 to 0.83) | 0.007 |
|
HF hospitalisationc | | | | |
Polypharmacy versus Controls | 2.66 (1.30 to 5.44) | 0.007 | 2.12 (1.02 to 4.40) | 0.043 |
Hyperpolypharmacy versus Controls | 4.25 (2.09 to 8.60) | <0.001 | 2.83 (1.37 to 5.86) | 0.005 |
Super hyperpolypharmacy versus Controls | 5.65 (2.77 to 11.55) | <0.001 | 3.00 (1.43 to 6.31) | 0.004 |
|
All-cause hospitalisationc | | | | |
Polypharmacy versus Controls | 1.75 (1.27 to 2.42) | 0.001 | 1.51 (1.09 to 2.10) | 0.014 |
Hyperpolypharmacy versus Controls | 2.26 (1.64 to 3.11) | <0.001 | 1.81 (1.29 to 2.53) | 0.001 |
Super hyperpolypharmacy versus Controls | 3.17 (2.28 to 4.42) | <0.001 | 2.29 (1.61 to 3.27) | <0.001 |
|
Myocardial infarctionc | | | | |
Polypharmacy versus Controls | 1.81 (0.55 to 5.97) | 0.33 | 1.31 (0.39 to 4.40) | 0.67 |
Hyperpolypharmacy versus Controls | 1.88 (0.57 to 6.19) | 0.30 | 1.11 (0.33 to 3.80) | 0.86 |
Super hyperpolypharmacy versus Controls | 3.37 (0.99 to 11.13) | 0.05 | 1.74 (0.46 to 6.51) | 0.41 |
|
Strokec | | | | |
Polypharmacy versus Controls | 1.82 (0.55 to 6.01) | 0.33 | 1.65 (0.49 to 5.50) | 0.42 |
Hyperpolypharmacy versus Controls | 1.40 (0.42 to 4.70) | 0.58 | 1.25 (0.35 to 4.39) | 0.73 |
Super hyperpolypharmacy versus Controls | 2.10 (0.62 to 7.16) | 0.23 | 1.92 (0.52 to 7.07) | 0.33 |